Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer.
We supply “sample to answer” Instrument, software and reagent solutions and are a market leader in targeted next-generation sequencing (NGS) in clinical research. Over the last decade, rapid advancements in NGS have enabled us to gain deep understanding of the underlying genomic alterations and biological pathways that lead to cancer development and progression, bringing hope to many oncology patients.
Precision Oncology enables better patient outcomes
Historically, cancer treatment followed a one-size-fits-all model, where therapies were selected based on the cancer type alone. As our understanding of cancer biology has grown, therapy decisions are now increasingly based on specific cancer biomarkers, or genetic alterations present in an individual’s cancer genome.
This individualized approach to cancer care is called “precision oncology.” Using a molecular profile of a patient’s cancer, treatment plans can be uniquely tailored to help provide the best potential outcome.
NGS: a key enabler of precision oncology
NGS has emerged as the platform of choice for tumor genomic profiling. This technology offers the possibility to assess multiple cancer biomarkers simultaneously in a single test to quickly reveal a full molecular profile, all while preserving tissue.
Our goal is to democratize NGS to enable any hospital in-house laboratory to provide comprehensive biomarker profile in time for the clinicians to make the best therapy decisions for their patient’s oncology.
We are on a mission, because precision oncology flourishes “in house”
We interviewed several experts around the globe, who share our belief that precision oncology should be practiced by coordinated, cross- functional teams close to the patients, including the genomic profiling. They all agreed, that:
- It is significantly faster and so it allows for fast and most optimal treatment decisions
- It is much more “tissue saving”, allowing for possible future testing if required
- It improves care coordination among multidisciplinary teams leading to true flexible personalized medicine
- It enables local expertise development which will be required in this field as precision medicine, driven by biomarker testing is the future
The Growing Importance of Next-Generation Sequencing in Myeloid Molecular Testing
Haematology has long been the proving ground for molecular testing. Like solid tumour testing, traditional molecular methods involve iterative single-analyte testing modalities, complex workflows, and frequent outsourcing to referencing laboratories, all of which results in a variable, often lengthy, turnaround times.
The use of NGS for routine clinical care in haematological malignancies is rapidly accelerating.
NGS enables cost-effective, efficient in-house testing of multiple biomarkers on targeted gene panels via streamlined, automated workflows and this method is transforming the testing paradigm and enabling better outcomes for patients, leading the way in precision medicine.
Oncomine Clinical Research Grants
The Oncomine Clinical Research Grant Program supports investigator-initiated studies (IIS) and education projects, on molecular testing in oncology, with the goal to increase high quality molecular profiling for patients and to improve clinical outcomes in the future.
Proposal reviews are conducted by independent and internationally recognized experts together with Thermo Fisher Scientific medical and scientific leadership. Funding is considered based on scientific merit and alignment with strategic areas of focus*.
*Terms and conditions apply. For complete details, go to www.oncomine.com/grants.
ESMO Virtual Congress 2020 Industry Satellite Symposium
NGS Biomarker testing: Time matters . No longer need to wait for weeks, as this can now happen within days
Thermo Fisher Scientific
L. Quagliata (Basel, Switzerland)
Genomic profiling is driving the precision oncology
P. Jermann (Basel, Switzerland)
Lung cancer diagnostic test needs: perspective from a thoracic oncologist
G. Fernandes (Porto, Portugal)
Establishment of a large-scale Asian genomic screening platform to identify non-small cell lung cancer with rare driver oncogenes and clarify drug resistant mechanisms
K. Goto (Kashiwa, Japan)
NTRK, RET and other fusion biomarkers testing: Latest developments
P. Jermann (Basel, Switzerland)
Follow us on social media
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.